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Variations of parathyroid 
hormone and bone biomarkers are 
concordant only after a long term 
follow-up in hemodialyzed patients
Pierre Delanaye1, Xavier Warling2, Martial Moonen2, Nicole Smelten3, François Jouret1, Jean-
Marie Krzesinski1, Nicolas Maillard4, Hans Pottel5 & Etienne Cavalier6
End-stage renal disease is associated with mineral and bone disorders. Guidelines recommending 
therapies should be based on serial assessments of biomarkers, and thus on variations (Δ), rather than 
scattered values. We analyzed the correlations between ΔPTH and Δbone biomarkers such as bone-
specific alkaline phosphatase (b-ALP), Beta-CrossLaps (CTX), osteocalcin, intact serum procollagen 
type-1 N-propeptide (P1NP), and tartrate-resistant acid phosphatase 5B (TRAP-5B) at different 
time-points. In this prospective observational analysis, variations of biomarkers were followed after 
6-week (n = 129), 6-month (n = 108) and one-year (n = 93) period. Associations between variations 
were studied by univariate linear regression. Patients followed for one-year period were classified 
(increaser or decliner) according to variations reaching the critical difference. Over the 6-week period, 
only ΔCTX was correlated with ΔPTH (r = 0.38, p < 0.0001). Over the one-year period, correlations 
between ΔPTH and Δbone biomarkers became significant (r from 0.23 to 0.47, p < 0.01), except with 
ΔTRAP-5b. Correlations between Δbone biomarkers were all significant after one-year period (r from 
0.31 to 0.68, p < 0.01), except between Δb-ALP and ΔTRAP-5b. In the head-to-head classifications 
(decliners/increasers), the percentage of concordant patients was significantly higher over the one-year 
than the 6-week period. A concordance between ΔPTH and Δbone biomarkers is observed in dialysis 
patients, but only after a long follow-up.
Chronic Kidney Disease (CKD) is associated with mineral and bone disorders (MBD). If bone health includes 
important concepts such as bone mineralization and bone volume, abnormalities in bone turnover remain key 
and specific to the dialysis population1. The gold standard for bone turnover diagnosis is bone biopsy2. However, 
such an invasive technique is difficult to apply in daily practice in every patient. Also, it is cumbersome to repeat 
such biopsies for bone turnover monitoring3. Therefore, nephrologists rely on bone biomarkers to monitor 
CKD-MBD1. The recent 2017 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines 
recommend to measure serum parathyroid hormone (PTH) and bone-specific alkaline phosphatase (b-ALP)4,5. 
However, the interpretation of these two parameters is not easy, notably because of lack of standardization in the 
dosages6–8. In cross-sectional studies, a good correlation is found between the two biomarkers3,9–11. However, 
their performance to predict bone turnover assessed by bone biopsies in transversal studies remains actually 
disappointing3,12–14. For this reason, the revised 2017 KDIGO guidelines suggest that potential CKD-MBD ther-
apies should be based on serial assessments of biomarkers, and thus on trends or variations (Δ), more than on 
one-single transversal result. In a previous work, we suggested that the correlations between variations of PTH 
(ΔPTH) and b-ALP (Δb-ALP) were poor11. This study was however retrospective and sample size was limited. In 
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the current work, we prospectively followed variations of PTH and other bone biomarkers on a 6-week, 6-month 
and one-year period.
Materials and Methods
Serum PTH and bone biomarker concentrations were measured in hemodialysis patients from three independent 
hospitals in Liège (Belgium) and surrounding areas (Centre Hospitalier Universitaire du Sart Tilman, Centre 
Hospitalier Regional de La Citadelle, Centre Hospitalier du Bois de l’Abbaye de Seraing) in 2013. All proce-
dures performed in the current study were in accordance with the ethical standards of the institutional research 
committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. 
The protocol was approved by the Ethics Committee of our institution “Comité d’éthique hospitalo-facultaire 
universitaire de Liège” (Belgian number study: B707201215885). Informed signed consent was obtained from all 
participants.
Samples were drawn in participating patients at baseline, then after 6 weeks, 6 months, and one year. Blood 
samples were collected before the first dialysis session of the week. Samples were immediately centrifuged and 
kept frozen at −80 °C until determination. Third-generation PTH (DiaSorin-Liaison, Stillwater, MN), intact 
serum procollagen type 1 N propeptide (P1NP), tartrate-resistant acid phosphatase 5B (TRAP-5B), osteocalcin, 
and Beta-CrossLaps (CTX)(IDS-iSYS, Boldon, UK) were measured in the same batch and in the same laboratory 
(department of Clinical Chemistry, University of Liège) accredited for the ISO 15189 Guideline. Inter-assay coef-
ficients of variation were below 10% for all measurements15. Serum calcium, phosphorus, C-reactive protein and 
albumin were also measured at baseline and after one-year period (Roche Cobas, Mannheim, Germany).
Data are expressed as mean ± standard deviation (SD) when distribution was normal and as median with 
interquartile range [IQR] when not. Normality was assessed by the Shapiro-Wilk test. In the transversal analysis, 
Pearson’s coefficients of correlation were calculated between PTH and bone biomarkers at baseline and after 
one-year. Then, three different analyses were done to study the variations of PTH and bone biomarkers over time. 
First, coefficients of correlation were calculated focusing on the variations of PTH (ΔPTH, in %) and bone bio-
markers (Δbone biomarkers, in %). Correlations between ΔPTH and Δbone biomarkers over a 6-week, 6-month 
and one-year period were thus calculated. Second, the concept of critical difference (CD) or least significant 
change was introduced in the analysis. In the field of Clinical Chemistry, CD represents the threshold from which 
a relative change between two consecutive measurements in the same patient is considered as significant. CD was 
previously determined for PTH, b-ALP, P1NP and TRAP-5b in the dialysis context15: 43%, 23%, 32% and 24%, 
respectively. As an example, a relative difference between two PTH consecutive results in the same patient can 
be considered as clinically relevant if it reached 43%. Patients were then classified according to these significant 
variations (stable, increaser or decliner). Classifications were compared by exact χ². Third, the slopes of different 
biomarkers were compared over one-year period (using the 4 available concentrations). Slopes were built and 
compared by simple linear regression and Pearson correlation. A p value of 0.008 was considered as significant 
after Bonferroni correction.
Results
Characteristics of the population. One hundred thirty-one patients signed the informed consent. Two 
patients were excluded from the analysis because of extreme PTH variations (from 36 to 1140 and from 1020 
to 67 pg/mL). Median age was 73.3 [18.1] year-old and 55.8% were men. During the follow-up, 36 patients 
dropped-out the analysis because of death (n = 18), loss of follow-up (n = 8), renal transplantation (n = 8) or 
hospitalization (n = 2). The total sample at baseline, after 6-week, 6-month and one-year was 129, 123, 108 and 
93, respectively. Clinical and biological characteristics at baseline and over one-year period are summarized in 
Table 1.
Pearson correlations. In the transversal analysis, a significant positive correlation was found between PTH 
and different bone biomarkers (except no correlation with TRAP-5B), both at baseline (r ranging from 0.42 to 
0.72, p < 0.0001) and after one-year follow-up (r ranging from 0.51 to 0.72, p < 0.0001) (Table 2). Significant pos-
itive correlations were also found between the different bone biomarkers at baseline (r ranging from 0.22 to 0.81, 
p < 0.01) and after one-year follow-up (r ranging from 0.22 to 0.82, p < 0.01).
By contrast, when the variations of concentrations are considered (ΔPTH and Δbone biomarkers), associ-
ations were much less solid than in the transversal analyses. Over the 6-week period (Table 3), only CTX was 
correlated with ΔPTH (r = 0.38, p < 0.0001). Also, several correlations between Δbone biomarkers were not 
significant. However, over the 6-month period (Table 3) and still more for the one-year period (Table 3), correla-
tions between ΔPTH and Δbone biomarkers became significant (r ranging from 0.23 to 0.47, p < 0.01 after one 
year), except for the absence of correlation between ΔPTH and ΔTRAP-5b. Also, correlations between Δbone 
biomarkers were all significant (and stronger than between ΔPTH and Δbone biomarkers) after one-year period 
(r ranging from 0.31 to 0.68, p < 0.01 after one year), except that no correlation existed between Δb-ALP and 
ΔTRAP-5b.
Critical difference. In this analysis, only the patients who fulfilled the entire one-year period (n = 93) 
were included. According to the respective CD of markers, the patients were classified as “stable”, “increaser” 
or “decliner”, at 6-week and one-year. As expected, the percentage of stable patients was higher after 6-week 
than one-year for all biomarkers (exact χ², p < 0.05), except for TRAP-5b. Head-to-head classifications (stable/
decliners/increasers) of different biomarkers are given over the 6-week and one-year period in Table 4. Globally, 
biomarkers similarly classified the patients in 38 to 72% of patients. Severe discordances (meaning that one bio-
marker significantly increased whereas the other actually significantly decreased) were found in 1 to 13% of 
patients. Results of head-to-head comparisons including TRAP-5b were systematically less good than with other 
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bone biomarkers. Concordances in classifications were slightly better between b-ALP and CTX than between 
PTH and b-ALP or PTH and intact P1NP. Concordances over a six-week period are better than over one-year 
period, but this analysis must be adjusted by the much higher percentage of stable patients in the 6-week period. 
Excluding stable patients and focusing on increasers and decliners, the percentage of concordant patients (i.e. the 
percentage of patients classified as decliners or increasers) was significantly higher over the one-year period in the 
head-to-head comparisons of biomarkers.
Slopes. Mean slopes were +0.77 ± 16.4 pg/mL/month, +1.13 ± 2.8 µg/L/month, +7.91 ± 158 ng/L/month, 
+5.93 ± 16.4 ng/mL/month, +4.58 ± 17.2 ng/mL/month, −0.04 ± 0.25 U/L/month/month for PTH, b-ALP, 
CTX, osteocalcin, P1NP and TRAP-5B, respectively. PTH slope was significantly correlated to CTX (r = 0.5, 
p < 0.0001), b-ALP (r = 0.41, p < 0.0001), and P1NP (r = 0.29, p = 0.004) slopes whereas no correlation was found 
between PTH slope and osteocalcin or TRAP-5b slopes. Apart from PTH, several pairs of biomarkers’ slopes 
displayed significant correlations. P1NP, b-ALP, CTX and osteocalcin slopes were significantly correlated, with a 
positive Pearson’s coefficient in every combination. TRAP-5B slope was only correlated to CTX. Pairs combina-
tions are displayed in Table 5 and Fig. 1.
Baseline 1-year
Sample 129 93
Age 73.3 [18.1] 74.1 [16.5]
Gender (% men) 55.8% 53.8%
Dry weight (kg) 71 [25] 71 [22]
Height (m) (n = 116) 1.63 ± 0.10 1.62 ± 0.10
BMI (kg/m²) (n = 116) 25.6 [9.9] 25.5 [9.9]
Diabetes (%) 42.2% 41.9%
Hypertension (%) 88.3% 85.0%
Dialysis vintage (month) 25.0 [39.0] 25.0 [39.0]
Therapy (%)
Calcium-based chelator 55.8% 50.0%
Non-Calcium based chelator 47.2% 43.6%
Native vitamin D 85.3% 80.4%
Active vitamin D 20.2% 29.8%
Cinacalcet 15.5% 23.4%
Serum calcium (mmol/L) 2.21 ± 0.17 2.20 ± 0.18
Serum phosphate (mmol/L) 1.55 [0.68] 1.49 [0.64]
Albumin (g/L) 39 ± 5 39 ± 5
C-reactive protein (mg/L) 4.8 [8.6] 4.2 [6.0]
25-OH vitamin D (ng/mL) 27.9 [24.6] 26.5 [23.3]
1,25 vitamin D (pg/mL) 18.4 [12.0] 14.7 [12.1]
PTH (pg/mL) 166 [175] 179 [216]
b-ALP (µg/L) 23.4 [17.9] 27.4 [31.3]*
CTX (ng/L) 2211 [2605] 1870 [2525]
Osteocalcin (ng/mL) 155 [194] 200 [270]
P1NP (ng/mL) 71 [62] 87 [106]*
TRAP-5b (U/L) 4.4 [2.9] 4.0 [3.5]
Table 1. Clinical and biological characteristics of the patients at baseline and after one-year follow-up. BMI: 
body mass index, *p < 0.05 between baseline and one-year result.
PTH b-ALP CTX osteocalcin P1NP TRAP-5b
PTH XXXXX 0.62 P < 0.0001 0.72 P < 0.0001 0.71 P < 0.0001 0.51 P < 0.0001 0.10 NS
b-ALP 0.57 P < 0.0001 XXXXX 0.75 P < 0.0001 0.61 P < 0.0001 0.78 P < 0.0001 0.22 P = 0.0332
CTX 0.72 P < 0.0001 0.72 P < 0.0001 XXXXX 0.82 P < 0.0001 0.79 P < 0.0001 0.44 P < 0.0001
Osteocalcin 0.72 P < 0.0001 0.70 P < 0.0001 0.81 P < 0.0001 XXXXX 0.53 P < 0.0001 0.25 P = 0.0157
P1NP 0.42 P < 0.0001 0.73 P < 0.0001 0.75 P < 0.0001 0.61 P < 0.0001 XXXX 0.52 P < 0.0001
TRAP-5b 0.06 NS 0.32 P = 0.0002 0.30 P = 0.0005 0.22 P = 0.0105 0.65 P < 0.0001 XXXXX
Table 2. Coefficient of correlation between biomarkers at baseline (Italic) and after one-year follow-up (bold). 
NS: not significant. Significant results in italic.
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Discussion
Variations of biomarkers, more than one-point result, are recommended by the KDIGO to assess the bone turn-
over of hemodialysis patients4. Indeed, cross-sectional studies showed that the performance of PTH, bone bio-
markers or even combinations of both is poor to predict the turnover determined by bone biopsy3,12–14. Changes 
in biomarkers over time are associated with mortality in dialysis patients16,17 and could also be better predictive of 
bone turnover observed by bone biopsy3. In the current analysis, we studied the evolution and, more specifically, 
the concordance between variations of biomarkers over time. If we confirmed that baseline or one-year results of 
PTH and bone biomarkers are highly correlated in cross-sectional analyses3,9–11, the correlations are much less 
relevant if the variations or changes of biomarkers are considered, suggesting that PTH and bone biomarkers give 
different information8. In this analysis, the variable “time” seems particularly important. Over a short period of 
time (6-week), no correlation can be found between PTH and bone biomarkers variations (except for CTX). The 
correlations between variations of PTH and bone biomarkers became however significant (except for TRAP-5b) 
after one year of follow-up. This point is confirmed both by considering two points comparison (baseline – 6 
weeks and baseline – one year) or comparison of slopes built with four points (baseline, 6 weeks, 6 months and 
one year). Similarly, the correlations between bone biomarkers are stronger over one-year than 6-week period, 
suggesting that the variations of bone biomarkers between them and still more variations of bone biomarkers and 
PTH must be interpreted on a relatively long period of time.
The classification of patients as stable, increasers or decliners is based on the critical difference of biomark-
ers, this variable having been previously determined for PTH, b-ALP, P1NP and TRAP-5b15. At first glance, it 
could be concluded that the concordance of classifications is better over a 6-week period than over one-year 
of follow-up. However, it must be reminded that most patients remain stable over the 6-week period. If stable 
patients are excluded from the analysis, it is clear that the concordance of both decliners and increasers are higher 
over the one-year period.
Globally, the results support a better concordance between variations of “true” bone biomarkers (P1NP, CTX, 
and b-ALP,) than between PTH and bone biomarkers, which is not fully unexpected as PTH is actually an indirect 
bone biomarker, since it is mainly influenced by calcium concentration8,18. Moreover, PTH concentrations rapidly 
follow any modification of calcium concentration, although other bone biomarkers take more time because their 
concentration will depend on the bone-remodelling process, which is about six months in healthy individuals. In 
the same view, the half-life of bone biomarkers in serum is expressed in days, whereas the half-life of PTH is only 
a few minutes8,19. Differences between the kinetics of the “minute to minute” calcium regulation by PTH, which 
has a short half-life, and the time needed for bone to be altered or improved, which is sometimes over 1 year have 
been illustrated in peritoneal dialysis patients moving to low calcium dialysate20 and in hemodialyzed patients 
treated by cinacalcet14,21.
Globally, the concordances are better between bone biomarkers, with the exception of TRAP-5b. Variations 
of P1NP and b-ALP over time seem particularly concordant. Moreover, concentrations of these two biomarkers 
(at least the intact form of P1NP) are not influenced by CKD status8,22, contrary to CTX3,8,23,24. The choice of 
one biomarker could be dependent on the availability of the biomarker in the laboratory and/or some specific 
characteristics of the patients (for instance, it has been suggested that severe hepatic dysfunction could interfere 
6-week n = 123 ΔPTH Δb-ALP ΔCTX Δosteocalcin ΔP1NP ΔTRAP-5b
ΔPTH XXXXX
Δb-ALP −0.08 NS XXXXX
ΔCTX 0.38 P < 0.0001 0.07 NS XXXX
ΔOsteocalcin −0.03 NS 0.31 P = 0.0004 0.15 NS XXXXX
ΔP1NP −0.14 NS 0.43 P < 0.0001 0.06 NS 0.52 P < 0.0001 XXXX
ΔTRAP-5b 0.04 NS −0.26 P = 0.0036 0.20 P = 0.0247 −0.07 NS −0.06 NS XXXXX
6-month 
n = 108 ΔPTH Δb-ALP ΔCTX Δosteocalcin ΔP1NP ΔTRAP-5b
ΔPTH XXXXX
Δb-ALP 0.11 NS XXXXX
ΔCTX 0.39 P < 0.0001 0.38 P < 0.0001 XXXX
ΔOsteocalcin 0.27 P = 0.0049 0.26 P = 0.007 0.32 P = 0.0008 XXXXX
ΔP1NP 0.07 NS 0.44 P < 0.0001 0.48 P < 0.0001 0.54 P < 0.0001 XXXX
ΔTRAP-5b 0.04 NS 0.03 NS 0.27 P = 0.0045 0.07 NS 0.24 P = 0.013 XXXXX
One-year n = 93 ΔPTH Δb-ALP ΔCTX Δosteocalcin ΔP1NP ΔTRAP-5b
ΔPTH XXXXX
Δb-ALP 0.29 P = 0.0054 XXXXX
ΔCTX 0.47 P < 0.0001 0.44 P < 0.0001 XXXX
ΔOsteocalcin 0.36 P = 0.0004 0.41 P < 0.0001 0.43 P < 0.0001 XXXXX
ΔP1NP 0.40 P = 0.0001 0.68 P < 0.0001 0.59 P < 0.0001 0.65 P < 0.0001 XXXX
ΔTRAP-5b 0.08 NS 0.14 NS 0.36 P = 0.0004 0.31 P = 0.0021 0.37 P = 0.0003 XXXXX
Table 3. Coefficient of correlation between variations (Δ) of biomarkers between baseline and 6-week 
(n = 123), 6-month (n = 108) and one-year (n = 93). NS: not significant. Significant results in italic.
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6-week (n = 93)
Increased b-ALP (Δb-
ALP >  + 23%)




Increased PTH (ΔPTH >  + 43%) 1 (1%) 13 (14%) 1 (1%)
PTH stable (ΔPTH within 43%) 14 (15%) 53 (56%) 1 (1%)
Decreased PTH (ΔPTH > −43%) 4 (4%) 4 (4%) 2 (2%)
One-year (n = 93) Increased b-ALP (Δb-ALP >  + 23%)




Increased PTH (ΔPTH >  + 43%) 17 (18%) 7 (8%) 0 (0%)
PTH stable (ΔPTH within 43%) 26 (28%) 27 (29%) 1 (1%)
Decreased PTH (ΔPTH > −43%) 4 (4%) 7 (8%) 4 (4%)
6-week (n = 93) Increased P1NP (P1NP > + 32%)




Increased PTH (ΔPTH >  + 43%) 4 (4%) 9 (10%) 2 (2%)
PTH stable (ΔPTH within 43%) 16 (17%) 50 (53%) 2 (2%)
Decreased PTH (ΔPTH > −43%) 5 (5%) 2 (2%) 3 (3%)
One-year (n = 93) Increased P1NP (P1NP > + 32%)




Increased PTH (ΔPTH >  + 43%) 19 (20%) 5 (5%) 0 (0%)
PTH stable (ΔPTH within 43%) 25 (28%) 28 (30%) 1 (1%)
Decreased PTH (ΔPTH > −43%) 3 (3%) 7 (7%) 5 (5%)





Increased PTH (ΔPTH > + 43%) 3 (3%) 8 (9%) 4 (4%)
PTH stable (ΔPTH within 43%) 12 (13%) 48 (51%) 8 (9%)
Decreased PTH (ΔPTH > −43%) 2 (2%) 3 (3%) 5 (5%)





Increased PTH (ΔPTH > + 43%) 4 (4%) 16 (17%) 4 (4%)
PTH stable (ΔPTH within 43%) 10 (11%) 29 (32%) 15 (16%)
Decreased PTH (ΔPTH > −43%) 1 (1%) 5 (5%) 9 (10%)
6-week (n = 93) Increased P1NP (P1NP > + 32%)





ALP > + 23%) 9 (10%) 7 (7%) 3 (3%)
b-ALP stable (Δb-ALP within 
43%) 15 (16%) 54 (58%) 1 (1%)
Decreased b-ALP (Δb-
ALP > −43%) 1 (1%) 0 (0%) 3 (3%)
One-year (n = 93) Increased P1NP (P1NP > + 32%)





ALP > + 23%) 33 (35%) 13 (14%) 1 (1%)
b-ALP stable (Δb-ALP within 
43%) 14 (15%) 25 (27%) 2 (2%)
Decreased b-ALP (Δb-
ALP > −43%) 0 (0%) 2 (2%) 3 (3%)






ALP > + 23%) 4 (4%) 5 (5%) 10 (11%)
b-ALP stable (Δb-ALP within 
43%) 11 (12%) 52 (56%) 7 (7%)
Decreased b-ALP (Δb-
ALP > −43%) 2 (2%) 2 (2%) 0 (0%)






ALP > + 23%) 11 (12%) 30 (32%) 6 (6%)
b-ALP stable (Δb-ALP within 
43%) 4 (4%) 20 (21%) 17 (18%)
Decreased b-ALP (Δb-
ALP > −43%) 0 (0%) 0 (0%) 5 (5%)
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with b-ALP measurement)8,25. Also from an analytical point of view, intact P1NP seems more robust than b-ALP6 
and is considered as the formation marker of choice by the International Osteoporosis Foundation26. The lower 
concordance observed with TRAP-5b could be explained by the fact that this biomarker is the only bone bio-
marker of osteoclastic activity (or, even more, a marker of osteoclasts number), the other being markers of bone 
formation8,27,28. In this context, it must be underlined that TRAP-5b classified many patients as decliners whereas 
decliners are minority with P1NP and b-ALP. TRAP-5b has also be proposed as an interesting biomarker for bone 
mass monitoring29.
There are limitations to our study. First, the study is purely observational and was neither designed nor pow-
ered to determine why and for which patients’ discrepant results are observed, notably according to their thera-
pies. Analyses were repeated after excluding 9 patients who changed their therapy (regarding cinacalcet or active 
vitamin D therapy) during the follow-up and the same conclusions remained (data not shown). The number of 
patients with changing therapy was definitively too low to be analyzed separately. A study with a similar design 
but focusing on patients starting cinacalcet or active vitamin D would be of interest. Second, in the absence of 
bone biopsy data, only a description of concordances and discrepancies in bone biomarkers evolution can be 
done but the potential superiority of one biomarker over another one to assess turnover cannot be proved. Third, 
because relative differences were used, the results could be too largely influenced by low PTH concentrations at 
6-week (n = 93)
Increased b-ALP (Δb-
ALP >  + 23%)





(ΔP1NP > + 32%) 8 (9%) 9 (10%) 8 (9%)
P1NP stable (ΔP1NP within 
32%) 8 (9%) 48 (52%) 5 (5%)
Decreased P1NP 
(ΔP1NP > −43%) 1 (1%) 2 (2%) 4 (4%)






(ΔP1NP > + 32%) 13 (14%) 27 (29%) 7 (7%)
P1NP stable (ΔP1NP within 
32%) 2 (2%) 22 (23%) 16 (17%)
Decreased P1NP 
(ΔP1NP > −43%) 0 (0%) 1 (1%) 5 (5%)
Table 4. Head-to-head comparison of biomarkers variations (increaser/stable/decliner) according to their 
respective critical difference. PTH versus b-ALP (6-week). Perfect concordance (bold cases): 56/93 = 60.2%. 
Discordance (roman cases): 32/93 = 34.4%. Severe discordance (italic cases): 5/93 = 5.4%. Percentage of 
perfect concordance (bold cases) excluding stable patients (the central bold case, n = 53)): 3/40 = 7.5%. PTH 
versus b-ALP (one-year). Perfect concordance (bold cases): 48/95 = 51.6%. Discordance (roman cases): 
41/93 = 44.1%. Severe discordance (italic cases): 4:93 = 4.3%. Percentage of perfect concordance (bold cases) 
excluding stable patients (the central bold case, n = 27)): 21/66 = 31.8%. PTH versus P1NP (6-week). Perfect 
concordance (bold cases): 57/93 = 61.3%. Discordance (roman cases): 29/93 = 31.2%. Severe discordance (italic 
cases): 7/93 = 7.5%. Percentage of perfect concordance (bold cases) excluding stable patients (the central bold 
case, n = 50)): 7/43 = 16.3%. PTH versus P1NP (one-year). Perfect concordance (bold cases): 52/93 = 55.9%. 
Discordance (roman cases): 38/93 = 40.9%. Severe discordance (italic cases): 3/93 = 3.2%. Percentage of 
perfect concordance (bold cases) excluding stable patients (the central bold case, n = 28)): 24/65 = 36.9%. 
PTH versus TRAP-5b (6-week). Perfect concordance (bold cases): 56/93 = 60.2%. Discordance (roman 
cases): 31/93 = 33.3%. Severe discordance (italic cases): 6/93 = 6.5%. Percentage of perfect concordance (bold 
cases) excluding stable patients (the central bold case, n = 48)): 8/45 = 17.8%. PTH versus TRAP-5b (one-
year). Perfect concordance (bold cases): 42/93 = 45.2%. Discordance (roman cases): 46/93 = 49.5%. Severe 
discordance (italic cases): 5/93 = 5.4%. Percentage of perfect concordance (bold cases) excluding stable patients 
(the central bold case, n = 29)): 13/64 = 20.3%. b-ALP versus P1NP (6-week). Perfect concordance (bold 
cases): 66/93 = 71%. Discordance (roman cases): 23/93 = 24.7%. Severe discordance (italic cases): 4/93 = 4.3%. 
Percentage of perfect concordance (bold cases) excluding stable patients (the central bold case, n = 54)): 
12/39 = 30.8%. b-ALP versus P1NP (one-year). Perfect concordance (bold cases): 61/93 = 65.6%. Discordance 
(roman cases): 31/93 = 33.3%. Severe discordance (italic cases): 1/93 = 1.1%. Percentage of perfect concordance 
(bold cases) excluding stable patients (the central bold case, n = 25)): 36/68 = 52.9%. b-ALP versus TRAP 5-b 
(6-week). Perfect concordance (bold cases): 56/93 = 60.2%. Discordance (roman cases): 25/93 = 26.9%. Severe 
discordance (italic cases): 12/93 = 12.9%. Percentage of perfect concordance (bold cases) excluding stable 
patients (the central bold case, n = 52)): 4/41 = 9.8%. b-ALP versus TRAP 5-b (one-year). Perfect concordance 
(bold cases): 36/93 = 38.7%. Discordance (roman cases): 51/93 = 54.8%. Severe discordance (italic cases): 
6/93 = 6.5%. Percentage of perfect concordance (bold cases) excluding stable patients (the central bold case, 
n = 20)): 16/73 = 21.9%. P1NP versus TRAP 5b (6-week). Perfect concordance (bold cases): 60/93 = 64.5%. 
Discordance (roman cases): 24/93 = 25.8%. Severe discordance (italic cases): 9/93 = 9.7%. Percentage of perfect 
concordance (bold cases) excluding stable patients (the central bold case, n = 48)): 12/45 = 26.7%. P1NP 
versus TRAP 5-b (one-year). Perfect concordance (bold cases): 40/93 = 43.0%. Discordance (roman cases): 
46/93 = 49.5%. Severe discordance (italic cases): 7/93 = 7.5%. Percentage of perfect concordance (bold cases) 
excluding stable patients (the central bold case, n = 22)): 18/71 = 25.3%.
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baseline. Analyses were thus repeated excluding patients with low turnover at baseline (defined as PTH lower 
than two-times the upper normal value) (n = 12) and the results remained the same (see supplements), suggesting 
that the level of PTH at baseline did not modify the conclusions. Lastly, our follow-up remains limited (one-year) 
and our population contains only prevalent dialysis patients. Further analyses in incident patients and with a still 
longer follow-up could be of interest.
Bone biomarkers have been suggested as of interest to detect bone turnover abnormalities in dialysis patients. 
A dynamic view and a focus on bone biomarkers modifications is promoted3,8. However, as illustrated in the 
present study, there are frequently discrepancies between the evolution of these different markers. One can rec-
ommend that results must be analyzed on a relatively long period of time because these bone biomarkers have 
certainly not the same reactivity to reflect bone activity, and this is especially true comparing PTH with bone 
biomarker. Moreover, a better concordance is observed between “true” bone formation biomarkers than between 
bone biomarkers and PTH (or marker of osteoclastic activity).
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